Trince, a spin-off company from Ghent University, has successfully raised $6.1 million in a recent funding round, securing significant investment to propel its innovative work. This capital infusion will support the company's mission to advance cell-based science and therapeutics by improving the precise and efficient delivery of molecules into cells, both in vitro and ex vivo.
At the core of Trince's innovation is its LumiPore transfection platform, which is protected by a portfolio of pending patents. This technology utilizes a unique approach combining laser exposure with photothermal nanoparticles. This process converts light energy into heat, leading to the transient permeabilization of the cellular plasma membrane. The LumiPore platform is designed to deliver a wide variety of effector molecules, such as nucleic acids or proteins, into virtually any cell type. This includes cells traditionally difficult to transfect, like immune cells crucial for cell therapies. The technology not only facilitates high-throughput genetic material delivery but also ensures a gentle process, which is vital for maximizing the therapeutic quality of the final cell product.
The $6.1 million in secured capital underscores investor confidence in Trince's proprietary technology and its potential to revolutionize cell engineering. Trince plans to strategically deploy these funds to accelerate the ongoing development and commercialization of its LumiPore platform. This investment will also enable the company to significantly scale its research and development initiatives, expand its operational footprint, and strengthen its team to meet anticipated market demand.
Looking ahead, Trince is focused on leveraging this funding to solidify its position as a leader in advanced cell transfection solutions, ultimately aiming to broaden the accessibility and efficacy of cell-based therapies.
